CL-197 is a long-acting purine-based nucleoside reverse transcriptase inhibitor (NRTI) with oral activity against HIV; it shows potential in research on viral infections, cancer, and cerebrovascular diseases; it serves as a click chemistry reagent containing an alkyne group that undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules.